News brief­ing: Glax­o­SmithK­line adds to flur­ry of deal­mak­ing; Take­da strikes $322M deal to of­fload a non-core port­fo­lio

As 2020 winds down, British drug­mak­er Glax­o­SmithK­line con­tin­ues a flur­ry of biotech deal­mak­ing — this time fo­cused on small mol­e­cule ther­a­peu­tics that tar­get trans­mem­brane pro­teins.

Through a col­lab­o­ra­tion with San Diego-based Lig­and Phar­ma­ceu­ti­cals and its sub­sidiary Ica­gen, the groups will work to iden­ti­fy and de­vel­op in­hibitors of a spe­cif­ic ge­net­i­cal­ly-val­i­dat­ed mol­e­c­u­lar tar­get rel­e­vant to neu­ro­log­i­cal dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.